David John Nutt (David J Nutt, D Nutt, David Nutt, D J Nutt)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 39

Top Topics

Autism Spectrum Disorder

Positron Emission Tomography

Top Venues

British journal of clinical pharmacology

Molecular psychiatry

This page only lists publications with an associated author ORCID identifier.

Publications

Michael T Nurmohamed, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne Katrin Schlag, David John Nutt
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21. Drugs & aging (2024)
Michael T Lynskey, Alkyoni Athanasiou-Fragkouli, Hannah Thurgur, Anne Katrin Schlag, David John Nutt
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence. BJPsych open 10 (2) (2024)
Michael T Nurmohamed, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne Katrin Schlag, David John Nutt
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21. Drugs & aging 41 (6) (2024)
Michael T Nurmohamed, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne Katrin Schlag, David John Nutt
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21. Drugs & aging 41 (6) (2024)
Michael T Nurmohamed, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne Katrin Schlag, David John Nutt
Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study. Archives of suicide research : official journal of the International Academy for Suicide Research (2024)
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Authors' response to letter 'On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long-COVID'. British journal of clinical pharmacology (2024)
Michael T Lynskey, Alkyoni Athanasiou-Fragkouli, Hannah Thurgur, Anne Katrin Schlag, David John Nutt
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence. BJPsych open 10 (2) (2024)
Michael T Nurmohamed, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne Katrin Schlag, David John Nutt
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21. Drugs & aging 41 (6) (2024)
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. British journal of clinical pharmacology 90 (4) (2024)
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. British journal of clinical pharmacology 90 (4) (2024)
Michael T Lynskey, Alkyoni Athanasiou-Fragkouli, Hannah Thurgur, Anne Katrin Schlag, David John Nutt
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence. BJPsych open 10 (2) (2024)
David John Nutt, Ilana Crome, Allan H Young
Is it now time to prepare psychiatry for a psychedelic future? The British journal of psychiatry : the journal of mental science (2024)
Matthew B Wall, Rebecca Harding, Rayyan Zafar, Eugenii A Rabiner, David John Nutt, David Erritzøe
Neuroimaging in psychedelic drug development: past, present, and future. Molecular psychiatry (2023)
Christopher Timmermann, Leor Roseman, Sharad Haridas, Fernando E Rosas, Lisa Luan, Hannes Kettner, Jonny Martell, David Erritzøe, Enzo Tagliazucchi, Carla Pallavicini, Manesh Girn, Andrea Alamia, Robert Leech, David John Nutt, Robin L Carhart-Harris
Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America 120 (13) (2023)
Christine A Parker, David John Nutt, Robin J Tyacke
Imidazoline-I2 PET Tracers in Neuroimaging. International journal of molecular sciences 24 (12) (2023)
Christine A Parker, David John Nutt, Robin J Tyacke
Imidazoline-I2 PET Tracers in Neuroimaging. International journal of molecular sciences 24 (12) (2023)
Balázs Szigeti, Lawrence D Phillips, David John Nutt
Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins. British journal of clinical pharmacology (2023)
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. British journal of clinical pharmacology (2023)
Sameer Jauhar, Danilo Arnone, David S Baldwin, Michael A P Bloomfield, Michael Browning, Anthony J Cleare, Philip Robert Corlett, John Francis William Deakin, David Erritzøe, Cynthia H Y Fu, Paolo Fusar-Poli, Guy M Goodwin, Joseph Hayes, Robert Howard, Oliver D Howes, Mário Francisco Juruena, Raymond W Lam, Stephen M Lawrie, Hamish McAllister-Williams, Steven Marwaha, David Matuskey, Robert A McCutcheon, David John Nutt, Carmine Maria Pariante, Toby Pillinger, Rajiv Radhakrishnan, James J H Rucker, Sudhakar Selvaraj, Paul Stokes, Rachel Upthegrove, Nefize Yalin, Lakshmi Yatham, Allan H Young, Roland Zahn, Philip J Cowen
A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Molecular psychiatry (2023)
Christine A Parker, David John Nutt, Robin J Tyacke
Imidazoline-I2 PET Tracers in Neuroimaging. International journal of molecular sciences 24 (12) (2023)
Christopher Timmermann, Leor Roseman, Sharad Haridas, Fernando E Rosas, Lisa Luan, Hannes Kettner, Jonny Martell, David Erritzøe, Enzo Tagliazucchi, Carla Pallavicini, Manesh Girn, Andrea Alamia, Robert Leech, David John Nutt, Robin L Carhart-Harris
Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences of the United States of America 120 (13) (2023)
Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag, Carol Croser, David John Nutt, Elizabeth Iveson
Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial. British journal of clinical pharmacology (2023)
Nicholas R Livingston, Valeria Calsolaro, Rainer Hinz, Joseph Nowell, Sanara Raza, Steve Gentleman, Robin J Tyacke, Jim Myers, Ashwin V Venkataraman, Robert Perneczky, Roger N Gunn, Eugenii A Rabiner, Christine A Parker, Philip S Murphy, Paul B Wren, David John Nutt, Paul M Matthews, Paul Edison
Relationship between astrocyte reactivity, using novel 11 C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular psychiatry 27 (4) (2022)
S Parker Singleton, Andrea I Luppi, Robin L Carhart-Harris, Josephine Cruzat, Leor Roseman, David John Nutt, Gustavo Deco, Morten L Kringelbach, Emmanuel Andreas Stamatakis, Amy F Kuceyeski
Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. Nature communications 13 (1) (2022)
David John Nutt, Robin J Tyacke, Meg Spriggs, Vanessa Jacoby, Alan D Borthwick, Delia Belelli
Functional Alternatives to Alcohol. Nutrients 14 (18) (2022)
Richard E Daws, Christopher Timmermann, Bruna Giribaldi, James D Sexton, Matthew B Wall, David Erritzoe, Leor Roseman, David John Nutt, Robin Carhart-Harris
Increased global integration in the brain after psilocybin therapy for depression. Nature medicine 28 (4) (2022)
S Rolles, David John Nutt, Anne Katrin Schlag
Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. The American journal of bioethics : AJOB 21 (4) (2021)
Luca Sforzini, Courtney Worrell, Melisa Kose, Ian M Anderson, Bruno Aouizerate, Volker Arolt, Michael Bauer, Bernhard T Baune, Pierre Blier, Anthony J Cleare, Philip J Cowen, Timothy G Dinan, Andrea Fagiolini, I Nicol Ferrier, Ulrich Hegerl, Andrew D Krystal, Marion Leboyer, R Hamish McAllister-Williams, Roger S McIntyre, Andreas Meyer-Lindenberg, Andrew H Miller, Charles B Nemeroff, Claus Normann, David John Nutt, Stefano Pallanti, Luca Pani, Brenda W J H Penninx, Alan F Schatzberg, Richard C Shelton, Lakshmi N Yatham, Allan H Young, Roland Zahn, Georgios Aislaitner, Florence Butlen-Ducuing, Christine Fletcher, Marion Haberkamp, Thomas Laughren, Fanni-Laura Mäntylä, Koen Schruers, Andrew Thomson, Gara Arteaga-Henríquez, Francesco Benedetti, Lucinda Cash-Gibson, Woo Ri Chae, Heidi De Smedt, Stefan M Gold, Witte J G Hoogendijk, Valeria Jordán Mondragón, Eduard Maron, Jadwiga Martynowicz, Elisa Melloni, Christian Otte, Gabriela Perez-Fuentes, Sara Poletti, Mark E Schmidt, Edwin van de Ketterij, Katherine Woo, Yanina Flossbach, Josep-Antoni Ramos-Quiroga, Adam J Savitz, Carmine Maria Pariante
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular psychiatry 27 (3) (2021)
Balázs Szigeti, Laura Kartner, Allan Blemings, Fernando E Rosas, Amanda Feilding, David John Nutt, Robin L Carhart-Harris, David Erritzoe
Self-blinding citizen science to explore psychedelic microdosing. eLife 10 (2021)
Valeria Calsolaro, Paul M Matthews, Cornelius K Donat, Nicholas R Livingston, Grazia D Femminella, Sandra Silva Guedes, Jim Myers, Zhen Fan, Robin J Tyacke, Ashwin V Venkataraman, Robert Perneczky, Roger Gunn, Eugenii A Rabiner, Steve Gentleman, Christine A Parker, Philip S Murphy, Paul B Wren, Rainer Hinz, Magdalena Sastre, David John Nutt, Paul Edison
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Molecular psychiatry (2021)
David John Nutt, Harriet de Wit
Putting the MD back into MDMA. Nature medicine 27 (6) (2021)
David John Nutt, Alexandra Hayes, Leon Fonville, Rayyan Zafar, Emily O C Palmer, Louise Paterson, Anne Lingford-Hughes
Alcohol and the Brain. Nutrients 13 (11) (2021)
Kristoffer A A Andersen, Robin Lester Carhart-Harris, David John Nutt, David Erritzøe
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta psychiatrica Scandinavica 143 (2) (2020)
Tiago Reis Marques, Abhishekh Hulegar Ashok, Ilinca Angelescu, Faith R Borgan, Jim Myers, Anne Lingford-Hughes, David John Nutt, Mattia Veronese, Federico E Turkheimer, Oliver D Howes
GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513. Molecular psychiatry 26 (6) (2020)
David John Nutt
New psychoactive substances: Pharmacology influencing UK practice, policy and the law. British journal of clinical pharmacology 86 (3) (2020)
David Erritzøe, Abhishekh H Ashok, Graham E Searle, Alessandro Colasanti, Samuel Turton, Yvonne Lewis, Mickael Huiban, Sara Moz, Jan Passchier, Azeem Saleem, John Beaver, Anne Lingford-Hughes, David John Nutt, Oliver D Howes, Roger N Gunn, Gitte M Knudsen, Eugenii A Rabiner
Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 45 (5) (2019)
Jamie Horder, Max Andersson, Maria A Mendez, Nisha Singh, Ämma Tangen, Johan Lundberg, Antony D Gee, Christer Halldin, Mattia Veronese, Sven Bölte, Lars Farde, Teresa Sementa, Diana Cash, Karen Higgins, Debbie Spain, Federico Turkheimer, Inge Mick, Sudhakar Selvaraj, David John Nutt, Anne Lingford-Hughes, Oliver D Howes, Declan G M Murphy, Jacqueline Borg
GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science translational medicine 10 (461) (2019)
Samuel Turton, James Fm Myers, Inge Mick, Alessandro Colasanti, Ashwin Venkataraman, Claire Durant, Adam Waldman, Alan Brailsford, Mark C Parkin, Gemma Dawe, Eugenii A Rabiner, Roger N Gunn, Stafford L Lightman, David John Nutt, Anne Lingford-Hughes
Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. Molecular psychiatry 25 (8) (2018)
E H Limbrick-Oldfield, I Mick, R E Cocks, J McGonigle, S P Sharman, A P Goldstone, P R A Stokes, A Waldman, D Erritzoe, H Bowden-Jones, David John Nutt, A Lingford-Hughes, L Clark
Neural substrates of cue reactivity and craving in gambling disorder. Translational psychiatry 7 (1) (2017)